Cover Image
Market Research Report

Thrombocythaemia Myelofibrosis - Pipeline Review, H2 2016

Published by Global Markets Direct Product code 201005
Published Content info 55 Pages
Delivery time: 1-2 business days
Price
Back to Top
Thrombocythaemia Myelofibrosis - Pipeline Review, H2 2016
Published: July 20, 2016 Content info: 55 Pages
Description

Summary:

Global Markets Direct's, 'Thrombocythaemia Myelofibrosis - Pipeline Review, H2 2016', provides an overview of the Thrombocythaemia Myelofibrosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Thrombocythaemia Myelofibrosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Thrombocythaemia Myelofibrosis and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape of Thrombocythaemia Myelofibrosis
  • The report reviews pipeline therapeutics for Thrombocythaemia Myelofibrosis by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Thrombocythaemia Myelofibrosis therapeutics and enlists all their major and minor projects
  • The report assesses Thrombocythaemia Myelofibrosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Thrombocythaemia Myelofibrosis

Reasons to buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Thrombocythaemia Myelofibrosis
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Thrombocythaemia Myelofibrosis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Product Code: GMDHC8245IDB

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Thrombocythaemia Myelofibrosis Overview
  • Therapeutics Development
    • Pipeline Products for Thrombocythaemia Myelofibrosis - Overview
    • Pipeline Products for Thrombocythaemia Myelofibrosis - Comparative Analysis
  • Thrombocythaemia Myelofibrosis - Therapeutics under Development by Companies
  • Thrombocythaemia Myelofibrosis - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
  • Thrombocythaemia Myelofibrosis - Products under Development by Companies
  • Thrombocythaemia Myelofibrosis - Companies Involved in Therapeutics Development
    • Celgene Corporation
    • Gilead Sciences, Inc.
    • Incyte Corporation
    • JW Pharmaceutical Corporation
    • Nippon Shinyaku Co., Ltd.
    • Novartis AG
    • Pfizer Inc.
  • Thrombocythaemia Myelofibrosis - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • buparlisib hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CWP-291 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • glasdegib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • itacitinib adipate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • momelotinib dihydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NS-018 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pomalidomide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Thrombocythaemia Myelofibrosis - Dormant Projects
  • Thrombocythaemia Myelofibrosis - Discontinued Products
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Thrombocythaemia Myelofibrosis, H2 2016
  • Number of Products under Development for Thrombocythaemia Myelofibrosis - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Thrombocythaemia Myelofibrosis - Pipeline by Celgene Corporation, H2 2016
  • Thrombocythaemia Myelofibrosis - Pipeline by Gilead Sciences, Inc., H2 2016
  • Thrombocythaemia Myelofibrosis - Pipeline by Incyte Corporation, H2 2016
  • Thrombocythaemia Myelofibrosis - Pipeline by JW Pharmaceutical Corporation, H2 2016
  • Thrombocythaemia Myelofibrosis - Pipeline by Nippon Shinyaku Co., Ltd., H2 2016
  • Thrombocythaemia Myelofibrosis - Pipeline by Novartis AG, H2 2016
  • Thrombocythaemia Myelofibrosis - Pipeline by Pfizer Inc., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Thrombocythaemia Myelofibrosis - Dormant Projects, H2 2016
  • Thrombocythaemia Myelofibrosis - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Thrombocythaemia Myelofibrosis, H2 2016
  • Number of Products under Development for Thrombocythaemia Myelofibrosis - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top